Aktis Oncology, Inc (NASDAQ:AKTS) has slipped in a September 2026 session, nudging the targeted-radiopharmaceutical developer back into focus during a busy stretch for freshly listed oncology names. Shares closed down 2.67% at $23.30 at last closing, a pullback that is modest by biotech standards, …
Few 2026 healthcare debutants have captured investor imagination like Alamar Biosciences, Inc. (NASDAQ:ALMR). The proteomics company priced its initial public offering in April 2026 and has since become a closely followed name in the liquid-biopsy and precision-medicine arena. Shares closed up 0.43% at $27.89 …
Annovis Bio, Inc. (NYSE: ANVS) will ask shareholders on October 14, 2026, to approve a charter amendment raising authorized common stock from 70,000,000 shares to 140,000,000 shares. The same proposal would increase authorized preferred stock from 2,000,000 shares to 10,000,000 shares. The special meeting …
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) awarded President and Head of R&D Miralles Gines Diego 45,000 shares at $0 per share on Sep. 9, 2026. The transaction was recorded under code A, an award or grant classification.
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) awarded Chief Medical Officer Banerjee Subhashis 30,000 shares at $0 per share on September 9, 2026. The same date also brought an award of 85,000 derivative securities.
AtaiBeckley Inc. (NASDAQ: ATAI) Chief Medical Officer Craig Kevin James disposed of 8,437 shares on 11 September 2026, leaving him with zero shares.
AtaiBeckley Inc. (NASDAQ: ATAI) shares totaling 216,442 were disposed of by Rao Srinivas across two transactions. His reported share holdings were zero after the transactions.
Barinthus Biotherapeutics plc. saw Oxford Science Enterprises plc transact 8,797,770 shares at $0.11 per share.
Aardvark Therapeutics, Inc. (NASDAQ: AARD) shares were sold by Sun Nelson in two transactions involving 76,754 shares. The reported sales leave Nelson with a stated post-transaction holding in the company’s shares.
ACADIA PHARMACEUTICALS INC (NASDAQ: ACAD) must notify stockholders about a proposed settlement in case 3:23-cv-02293 after a federal court granted preliminary approval on August 24, 2026. If approved, the resolution would affect holders’ rights to challenge the settlement and pursue released claims.